Bacterial colonisation of the nasopharynx leads

to a generally asymptomatic carrier state, which acts as the source for person-to-person transmission. Colonisation with more than one serotype at a time is relatively common, and competition between serotypes for colonisation of the human host is known to occur. Therefore, following initial observations that bacterial conjugate vaccines reduce nasopharyngeal Selleck RG 7204 colonisation with vaccine serotypes (VT) [1], [2] and [3], the implication that this would have on disease was intriguing. Use of bacterial conjugate vaccines in infant immunisation programmes has in addition to direct protection, resulted in an observed reduction in invasive disease in both unvaccinated children and adults [4] and [5]. In some settings the indirect effect seen accompanying the use of pneumococcal conjugate vaccines (PCV) in infants has been responsible for more disease reduction than the direct effect [6] and has thus driven cost effective calculations. The consequence of reducing or even VE-821 supplier eradicating the most prevalent pneumococcal serotypes from the nasopharynx has been an increase (replacement) in colonisation by non-vaccine serotypes that have the potential to cause disease (there are approximately 94 different pneumococcal

types (serotypes) identified). Colonisation endpoints are important in phase III or IV pneumococcal vaccine studies for a variety of biologic and practical reasons. Firstly, because pneumococcal colonisation is a precondition to pneumococcal disease, vaccine effects on colonisation may at the individual level serve as markers of vaccination-induced protection against various disease

manifestations [7]. Secondly, the public health impact of pneumococcal vaccination in the wider population, including the indirect and overall effectiveness of vaccination, depends on the level of direct protection against colonisation. Thirdly, because the incidence and prevalence of pneumococcal colonisation are higher than those of disease, studies with a colonisation endpoint are easier to conduct and require smaller sample sizes than studies with 4-Aminobutyrate aminotransferase a disease endpoint. Fourthly, in phase III trials, in which the direct vaccine efficacy is of interest, indirect effects of vaccination or other confounding factors are less likely to interfere with the measurement of vaccine efficacy due to the shorter time period for data collection. Finally, unlike the currently applied immunological criteria for PCV licensure [8] and [9], colonisation endpoints can be more directly estimated for each serotype and may thus serve as a better assessment of true biological efficacy. Despite the obvious relevance of colonisation data, the interpretation of efficacy against colonisation across different studies may be confounded by the variability of study designs employed [10].